echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > FDA accelerates approval of GlaxoSmithKline PD-1 antibody to treat patients with specific endometrial cancer

    FDA accelerates approval of GlaxoSmithKline PD-1 antibody to treat patients with specific endometrial cancer

    • Last Update: 2021-05-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, the US FDA announced that it has accelerated the approval of the anti-PD-1 antibody Jemperli (dostarlimab) developed by GlaxoSmithKline (GSK) to treat patients with relapsed or advanced endometrial cancer.


    Endometrial cancer is the sixth most common cancer among women in the world.


    Jemperli is a humanized anti-PD-1 monoclonal antibody.


    The safety and effectiveness of Jemperli are supported by a single-arm, multi-cohort clinical trial.


    Reference materials:

    [1] FDA Approves Immunotherapy for Endometrial Cancer with Specific Biomarker.


    Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.